A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin plus Olaratumab versus Doxorubicin plus Placebo in Patients with Advanced or Metastatic Soft Tissue Sarcoma
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Eli Lilly and Company
Start Date
December 1, 2015
End Date
November 30, 2020
Administered By
Duke Cancer Institute
Awarded By
Eli Lilly and Company
Start Date
December 1, 2015
End Date
November 30, 2020